...
首页> 外文期刊>European journal of gastroenterology and hepatology >Clinical phenotype and mortality in patients with idiopathic small bowel villous atrophy: a dual-centre international study
【24h】

Clinical phenotype and mortality in patients with idiopathic small bowel villous atrophy: a dual-centre international study

机译:特发性小肠绒毛萎缩患者的临床表型和死亡率:双中心国际研究

获取原文
获取原文并翻译 | 示例
           

摘要

Objective Causes of small-bowel villous atrophy (VA) include coeliac disease (CD), its complications and other rare non-coeliac enteropathies. However, forms of VA of unknown aetiology may also exist. We defined them as idiopathic VA (IVA). To retrospectively classify the largest cohort of IVA patients and compare their natural history with CD. Methods Notes of 76 IVA patients attending two tertiary centres between January 2000 and March 2019 were retrospectively reviewed. CD, its complications and all the known causes of VA were excluded in all of them. Persistence of VA during follow-up and lymphoproliferative features were used to retrospectively classify IVA, as follows. Group 1: IVA with spontaneous histological recovery (50 patients). Group 2: persistent IVA without lymphoproliferative features (14 patients). Group 3: persistent IVA with lymphoproliferative features (12 patients). Survival was compared between IVA groups and 1114 coeliac patients. HLA was compared between IVA patients, coeliac patients and appropriate controls. Results Five-year survival was 96% in IVA group 1, 100% in IVA group 2, 27% in IVA group 3 and 97% in CD. On a multivariate analysis hypoalbuminemia (P= 0.002) and age at diagnosis (P= 0.04) predicted mortality in IVA. Group 2 showed association with HLA DQB1*0301 and DQB1*06. Conclusion IVA consists of three groups of enteropathies with distinct clinical phenotypes and prognoses. Mortality in IVA is higher than in CD and mainly due to lymphoproliferative conditions necessitating more aggressive therapies.
机译:小肠绒毛萎缩(VA)的客观原因包括腹腔疾病(CD),其并发症和其他罕见的非乳糜肠病。然而,也存在未知的病症的VA形式。我们将其定义为特发性VA(IVA)。回顾性地分类IVA患者最大的群组,并将其与CD的自然历史进行比较。方法回顾性审查了2000年1月至2019年3月在2019年1月至2019年3月间的76名IVA患者的说明。 CD,其并发症和VA的所有已知原因被排除在所有这些中。如下,使用随访和淋巴移植特征期间VA的持久性,如下所述。第1组:IVA具有自发组织学恢复(50名患者)。第2组:持久性IVA没有淋巴抑制剂特征(14名患者)。第3组:持久性IVA具有淋巴抑制性特征(12名患者)。在IVA组和1114名乳糜烃患者之间比较生存。在IVA患者,乳糜泻患者和适当的对照之间进行了比较HLA。结果5年生存率在IVA组1中为96%,IVA组中的100%,IVA组2,27%,CD中97%。在多变量分析中,低聚蛋白血症(P = 0.002)和诊断年龄(P = 0.04)IVA中的死亡率。第2组显示与HLA DQB1 * 0301和DQB1 * 06的关联。结论IVA由三组肠病组成,具有不同的临床表型和预期。 IVA的死亡率高于CD,主要是由于淋巴抑制性条件需要更具侵略性的疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号